+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06619587

Evaluating the Safety and Activity of GDC-7035 Alone and with Other Therapies in Advanced Solid Tumors with KRAS G12D Mutation

Led by Genentech, Inc. · Updated on 2026-10-23

410

Participants Needed

49

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, pharmacokinetics, and early activity of GDC-7035, both alone and combined with other anti-cancer therapies, in adults with advanced or metastatic solid tumors that have the KRAS G12D mutation. This first-in-human Phase III study is open-label and conducted at multiple centers, focusing on patients with this specific genetic tumor marker. Participants receive GDC-7035 in two study arms one with GDC-7035 alone and the other with GDC-7035 combined with other anti-cancer treatments. The study involves dose escalation and expansion phases with protocol-defined dosing to determine safe and effective dose levels. During the trial, participants are closely monitored for side effects, dose-limiting toxicities, and blood levels of the drug at specified times. Researchers measure response rates, duration of response, and progression-free survival over a period of up to four years. The study involves regular evaluations to assess safety and drug activity throughout the treatment period.

CONDITIONS

Brief Title

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Research Team

R

Reference Study ID Number: GO45416 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here